LeMaitre Vascular (LMAT) Financials

LeMaitre Vascular Inc (LMAT) is a medical device company specializing in the development, manufacturing, and marketing of medical devices for the treatment of peripheral vascular disease. The company's products include vascular grafts, endovascular stents, and other surgical instruments used in vascular procedures. LeMaitre Vascular Inc's total revenue for the fiscal year ending December 31, 2020, was $111 million, with a gross profit of $79 million. The company's net income from stockholders was $11.5 million. LeMaitre Vascular Inc's balance sheet as of December 31, 2020, showed total assets of $191.5 million, total debt of $53.8 million, and total liabilities of $88.3 million. The company's stockholders' equity was $103.2 million. LeMaitre Vascular Inc had cash equivalents of $44.7 million and net debt of $9.8 million. The company's operating cash flow for 2020 was $17.2 million, while the financing cash flow was -$6.1 million. LeMaitre Vascular Inc generated a free cash flow of $11.1 million and an investing cash flow of -$7.5 million.

LeMaitre Vascular Inc's EBIT for the fiscal year ending December 31, 2020, was $17.3 million, while the EBITDA was $20.1 million. The company's financials demonstrate its strong performance and stability in the medical device industry. With a focus on innovation and delivering high-quality products, LeMaitre Vascular Inc has established itself as a leader in the field. The company's commitment to providing advanced solutions for vascular disease treatment has contributed to its success. LeMaitre Vascular Inc continues to invest in research and development to stay at the forefront of medical technology. Its solid financial position and strong cash flow enable the company to pursue new opportunities and expand its product portfolio. With a dedicated team and a customer-centric approach, LeMaitre Vascular Inc is well-positioned for future growth and continued success.